Patent · US Active

Solid oral formulation of fenretinide

US10406127B2 · kind B2 · utility

3Cited by

11References

32Claims

0Family size

Assignee

LAURENT PHARMACEUTICALS · CA

Inventors

Aimesther Betancourt · Montréal, CA
Marc Lemieux · Sanford, US
Roch Thibert · Mount Royal, CA

Key dates

Filing date	Jul 24, 2015
Grant date	Sep 10, 2019
Priority date	—
Expiry date	Jul 24, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/146
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Amorphous solid dispersions suitable for oral delivery comprising fenretinide or an analog thereof and at least one matrix polymer, and processes for making the dispersions, are disclosed. Also disclosed are solid oral formulations comprising the amorphous solid dispersions, as well as uses thereof for the prevention and/or treatment of diseases or conditions treatable by fenretinide, including but not limited to cancers, conditions associated with a lipid imbalance, cystic fibrosis, osteoporosis, conditions associated with inflammation or opportunistic infections, and other diseases such as diabetes, obesity, dry-form age-related macular degeneration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.